natgillin/translations-raw huggingface dataset:
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. 
Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na pretisnem omotu in škatli poleg oznake EXP oziroma Uporabno do. Rok uporabnosti se izteče na zadnji dan navedenega meseca.
Each 100 mg film-coated tablet contains 69.21 mg Lactose monohydrate. 
Vsaka 100-mg filmsko obložena tableta vsebuje 69,21 mg laktoze monohidrata.
Each 150 mg film-coated tablet contains 103.82 mg Lactose monohydrate. 
Vsaka 150-mg filmsko obložena tableta vsebuje 103,82 mg laktoze monohidrata.
Hazard Ratio (95% CI) 
(95-% IZ)
What you need to know before you take Tarceva Do not take Tarceva: 
Kaj morate vedeti, preden boste vzeli zdravilo Tarceva
Erlotinib and coumarin-derived anticoagulants 
Erlotinib in kumarinski antikoagulanti
Exploratory Analysis (40% OS maturity) (n=173) 
Eksplorativna analiza (s 40 % podatkov za celokupno preživetje) (n = 173)
This study was conducted in Caucasian patients with metastatic or locally advanced NSCLC (stage IIIB and IV) who have not received previous chemotherapy or any systemic antitumour therapy for their advanced disease and who present mutations in the tyrosine kinase domain of the EGFR (exon 19 deletion or exon 21 mutation). 
V študijo so bili vključeni belci z lokalno napredovalim ali metastatskim nedrobnoceličnim rakom pljuč (stopnja IIIB in IV), ki za napredovalo bolezen niso prejeli predhodne kemoterapije ali kakršnekoli druge sistemske protitumorne terapije in pri katerih so bile prisotne mutacije v tirozin kinazni domeni EGFR (delecija eksona 19 ali mutacija eksona 21).
Erlotinib and medicinal products altering pH 
Z erlotinibom in zdravili spremenjen pH
In the 45% of patients with known EGFR-expression status, the hazard ratio was 0.68 (95% CI 0.49-0.94) for patients with EGFR-positive tumours and 0.93 (95% CI 0.63-1.36) for patients with EGFR-negative tumours (defined by IHC using EGFR pharmDx kit and defining EGFR-negative as less than 10% tumour cells staining). 
Pri 45 % bolnikov z znanim statusom ekspresije EGFR, je bilo za bolnike z EGFR-pozitivnimi tumorji razmerje ogroženosti 0,68 (95-% interval zaupanja: 0,49-0,94), za bolnike z EGFR-negativnimi tumorji pa 0,93 (95-% interval zaupanja: 0,63-1,36); status ekspresije EGFR so določili z imunohistokemijo, z uporabo EGFR pharmDx kita.
Erlotinib is excreted predominantly as metabolites via the faeces (>90%) with renal elimination accounting for only a small amount (approximately 9%) of an oral dose. 
Erlotinib se po peroralnem dajanju v glavnem izloča v obliki presnovkov z blatom (> 90 %), v manjšem obsegu pa tudi prek ledvic (približno 9 %).
No data are available regarding the influence of severe hepatic dysfunction on the pharmacokinetics of erlotinib. 
Podatkov glede vpliva hude jetrne disfunkcije na farmakokinetiko erlotiniba ni.
Diarrhoea and vomiting (very common: may affect more than 1 out of 10 people). 
• Driska in bruhanje (zelo pogosta: pojavita se lahko pri več kot 1 od 10 bolnikov).
• if you are also taking a statin and experience unexplained muscle pain, tenderness, weakness or cramps. 
• sočasno jemljete statin in se pri vas pojavijo nerazložljive bolečine v mišicah, občutljivost mišic na dotik, mišična šibkost ali krči.
In the clinical studies doses were reduced by 50 mg steps. 
V kliničnih študijah so odmerke zmanjševali v korakih po 50 mg. Zmanjševanja odmerkov po 25 mg niso proučili.
When considering the use of Tarceva as a first line or maintenance treatment for locally advanced or metastatic NSCLC, it is important that the EGFR mutation status of a patient is determined. 
Pri odločanju o uporabi zdravila Tarceva v prvi liniji zdravljenja ali za vzdrževalno zdravljenje lokalno napredovalega ali metastatskega nedrobnoceličnega raka pljuč je pomembno, da se določi bolnikov status mutacij EGFR.
• Eyebrow changes 
• spremembe trepalnic,
In the pivotal Phase III NSCLC trial, current smokers achieved erlotinib steady state trough plasma concentration of 0.65 µg/mL (n=16) which was approximately 2-fold less than the former smokers or patients who had never smoked (1.28 µg/mL, n=108). 
V ključni študiji faze III pri nedrobnoceličnem raku pljuč je bila najmanjša koncentracija erlotiniba v stanju dinamičnega ravnovesja pri bolnikih, ki so med zdravljenjem kadili, 0,65 µg/ml (n = 16), kar je bilo približno 2-krat manj, kot pri nekdanjih kadilcih ali bolnikih, ki niso nikoli kadili (1,28 µg/ml, n = 108).
Liver or kidney disease 
Bolezen jeter ali ledvic
How to take Tarceva 
Kako jemati zdravilo Tarceva
EU/1/05/311/002 
EU/1/05/311/001 EU/1/05/311/002 EU/1/05/311/003
In some cases these medicines may reduce the efficacy or increase the side effects of Tarceva and your doctor may need to adjust your treatment. 
V nekaterih primerih lahko ta zdravila zmanjšajo učinkovitost ali pa povečajo neželene učinke zdravila Tarceva, zato bo morda zdravnik moral prilagoditi vaše zdravljenje ali pa vas med jemanjem zdravila Tarceva s temi zdravili ne bo zdravil;
If the use of ranitidine is considered, it should be used in a staggered manner; i.e. Tarceva must be taken at least 2 hours before or 10 hours after ranitidine dosing. 
Če razmišljamo o uporabi ranitidina, moramo zdravili jemati ločeno: zdravilo Tarceva je treba vzeti najmanj 2 uri pred ali 10 ur po odmerku ranitidina.
If you are exposed to sun, protective clothing, and/or use of sunscreen (e.g. mineral-containing) may be advisable Infection 
Če ste izpostavljeni soncu, je verjetno koristno uporabiti zaščitna oblačila in/ali zaščitno kremo za sonce (npr. na osnovi mineralov);
In patients who develop acute onset of new and/or progressive unexplained pulmonary symptoms such as dyspnoea, cough and fever, Tarceva therapy should be interrupted pending diagnostic evaluation. 
Pri bolnikih, pri katerih se akutno pojavijo novi in/ali poslabšajo nepojasnjeni pljučni simptomi, kot so dispneja, kašelj in zvišana telesna temperatura, je treba zdravljenje z zdravilom Tarceva prekiniti, dokler ni znana diagnoza.
• Infection of hair follicles 
• okužbe lasnih mešičkov,
Combination of erlotinib with proton pump inhibitors should be avoided. 
Kombinaciji erlotiniba in zaviralcev protonske črpalke se je treba izogibati.
Use of Tarceva in patients with severe renal impairment is not recommended. 
Uporaba zdravila Tarceva pri bolnikih s hudo ledvično okvaro ni priporočljiva.
In an open-label, randomised phase III study, ML20650 conducted in 154 patients, the safety of Tarceva for first-line treatment of NSCLC patients with EGFR activating mutations was assessed in 75 patients; no new safety signals were observed in these patients. 
V odprti, randomizirani študiji faze III, ML20650, ki je vključevala 154 bolnikov, so varnost zdravila Tarceva v prvi liniji zdravljenja proučevali pri 75 bolnikih z nedrobnoceličnim rakom pljuč z EGFRaktivirajočimi mutacijami.
Diarrhoea, dehydration, electrolyte imbalance and renal failure Diarrhoea (including very rare cases with a fatal outcome) has occurred in approximately 50% of patients on Tarceva and moderate or severe diarrhoea should be treated with e.g. loperamide. 
Driska, dehidracija, neravnovesje elektrolitov in ledvična odpoved Pri približno 50 % bolnikov, ki so se zdravili z zdravilom Tarceva, se je pojavila driska (vključno z zelo redkimi primeri, ki so se končali s smrtnim izidom).
Erlotinib is a potent inhibitor of CYP1A1, and a moderate inhibitor of CYP3A4 and CYP2C8, as well as a strong inhibitor of glucuronidation by UGT1A1 in vitro. 
Erlotinib je močan zaviralec CYP1A1, srednje močan zaviralec CYP3A4 in CYP2C8, kot tudi močan zaviralec glukuronidacije z UGT1A1 in vitro.
In a clinical study, the concomitant use of erlotinib and rifampicin (600 mg orally once daily for 7 days), a potent CYP3A4 inducer, resulted in a 69% decrease in the median erlotinib AUC. 
V klinični študiji je sočasna uporaba erlotiniba in močnega induktorja CYP3A4, rifampicina (600 mg peroralno enkrat na dan 7 dni), povzročila 69-% zmanjšanje mediane AUC erlotiniba.
Tarceva is also indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen. 
Zdravilo Tarceva je indicirano tudi za zdravljenje bolnikov z lokalno napredovalim ali metastatskim nedrobnoceličnim rakom pljuč po neuspehu vsaj ene predhodne kemoterapije.
In a study of 4 patients (3 with non-small cell lung cancer [NSCLC], and 1 with laryngeal cancer) receiving 150 mg daily oral doses of Tarceva, tumour samples from surgical excisions on Day 9 of treatment revealed tumour concentrations of erlotinib that averaged 1185 ng/g of tissue. 
V študiji štirih bolnikov (trije so imeli nedrobnocelični rak pljuč, eden pa rak grla), ki so prejemali zdravilo Tarceva v odmerku 150 mg enkrat na dan peroralno, so po kirurškem izrezu v vzorcih tumorjev na deveti dan zdravljenja koncentracije erlotiniba znašale v povprečju 1185 ng/g tkiva.
In more severe or persistent cases of diarrhoea, or cases leading to dehydration, particularly in groups of patients with aggravating risk factors (especially concomitant chemotherapy and other medications, symptoms or diseases or other predisposing conditions including advanced age), Tarceva therapy should be interrupted and appropriate measures should be taken to intensively rehydrate the patients intravenously. 
Posebno pri bolnikih z dejavniki tveganja (zlasti sočasnim jemanjem kemoterapevtikov in drugih zdravil, simptomi ali boleznimi ali drugimi dejavniki, vključno z visoko starostjo) moramo, če je driska huda ali dolgotrajna oziroma vodi v dehidracijo, zdravljenje z zdravilom Tarceva prekiniti in bolnikom zagotoviti intenzivno intravensko rehidracijo.
In the Tarceva plus gemcitabine arm, Grade 3/4 rash and diarrhoea were each reported in 5% of patients. 
V skupini, ki je prejemala zdravilo Tarceva in gemcitabin, so o kožnem izpuščaju in driski, obeh stopnje 3/4, poročali obakrat pri 5 % bolnikov.
The safety and efficacy of erlotinib has not been studied in patients with severe hepatic dysfunction (AST/SGOT and ALT/SGPT> 5 x ULN). 
Varnosti in učinkovitosti erlotiniba pri bolnikih s hudo jetrno disfunkcijo (AST/SGOT in ALT/SGPT > petkratna zgornja meja normalne vrednosti) niso proučevali.
Tarceva resulted in symptom benefits by significantly prolonging time to deterioration in cough, dyspnoea and pain, versus placebo. 
V primerjavi s placebom je zdravilo Tarceva signifikantno podaljšalo čas do poslabšanja simptomov kašlja, dispneje in bolečine.
The listed ADRs were those reported in at least 10% (in the Tarceva group) of patients and occurred more frequently (≥3%) in patients treated with Tarceva than in the comparator arm. Other ADRs including those from other studies are summarized in Table 2. 
O navedenih neželenih učinkih so poročali pri najmanj 10 % bolnikov (v skupini, zdravljeni z zdravilom Tarceva) in so se pri bolnikih, zdravljenih z zdravilom Tarceva, pojavljali bolj pogosto (≥ 3 %) kot v primerjalni skupini.
The median overall survival was 6.7 months in the Tarceva group (95% CI, 5.5 to 7.8 months) compared with 4.7 months in the placebo group (95% CI, 4.1 to 6.3 months). 
Mediana celokupnega preživetja je bila v skupini, ki je jemala zdravilo Tarceva, 6,7 meseca (95-% interval zaupanja; 5,5-7,8 meseca), v primerjavi s 4,7 meseca v placebo skupini (95-% interval zaupanja; 4,1-6,3 meseca).
In this study, the overall population showed a benefit for the primary PFS end-point (HR= 0.71 p< 0.0001) and the secondary OS end-point (HR= 0.81 p=0.0088). 
Ta študija je pokazala korist za celotno populacijo pri primarnem cilju, preživetju brez napredovanja bolezni (razmerje ogroženosti = 0,71, p <0,0001), in sekundarnem cilju, celokupnem preživetju (razmerje ogroženosti = 0,81, p = 0,0088).
A higher incidence of ILD (approximately 5% with a mortality rate of 1.5%) is seen among patients in studies conducted in Japan. 
Pri bolnikih iz študij, izvedenih na Japonskem, so opazili višjo incidenco intersticijske bolezni pljuč (približno 5-%, z 1,5-% umrljivostjo).
QUALITATIVE AND QUANTITATIVE COMPOSITION Tarceva 25 mg film coated tablets 
KAKOVOSTNA IN KOLIČINSKA SESTAVA Tarceva 25 mg filmsko obložene tablete
Concomitant administration of Tarceva with 300 mg ranitidine, an H2-receptor antagonist, decreased erlotinib exposure [AUC] and maximum concentrations [Cmax] by 33% and 54%, respectively. 
Sočasno dajanje zdravila Tarceva in 300 mg ranitidina, antagonista receptorjev H2, je zmanjšalo izpostavljenost erlotinibu [AUC] za 33 % in maksimalno koncentracijo [Cmax] za 54 %.
In a phase I dose escalation study in NSCLC patients who were current smokers, pharmacokinetic analyses at steady-state indicated a dose proportional increase in erlotinib exposure when the Tarceva dose was increased from 150 mg to the maximum tolerated dose of 300 mg. Steady-state trough plasma concentrations at a 300 mg dose in current smokers in this study was 1.22 µg/mL (n=17). 
V študiji faze I s povečevanjem odmerka pri bolnikih z nedrobnoceličnim rakom pljuč so farmakokinetične analize v stanju dinamičnega ravnotežja pri bolnikih, ki so kadili, pokazale od odmerka odvisno povečanje izpostavljenosti erlotinibu, ko se je odmerek zdravila Tarceva povečeval iz 150 mg do največjega odmerka, ki so ga še prenašali, 300 mg. Najmanjša plazemska koncentracija v stanju dinamičnega ravnovesja pri 300 mg odmerku pri kadilcih je bila v tej študiji 1,22 µg/ml (n = 17).
Medicinal products that alter the pH of the upper Gastro-Intestinal (GI) tract may alter the solubility of erlotinib and hence its bioavailability. 
Zdravila, ki spremenijo pH v zgornjem delu prebavil, lahko spremenijo topnost erlotiniba in posledično njegovo biološko uporabnost.
Confounding or contributing factors such as concomitant or prior chemotherapy, prior radiotherapy, pre-existing parenchymal lung disease, metastatic lung disease, or pulmonary infections were frequent. 
Pogosto so bili prisotni tudi dejavniki, ki lahko pripomorejo k nastanku teh bolezni, kot so sočasna ali predhodna kemoterapija, predhodna radioterapija, predhodno obstoječa parenhimska pljučna bolezen, metastatska pljučna bolezen ali pljučne okužbe.
INFORMATION IN BRAILLE tarceva 25 mg 
PODATKI V BRAILLOVI PISAVI tarceva 25 mg
Erlotinib potently inhibits the intracellular phosphorylation of EGFR. 
Erlotinib močno zavira znotrajcelično fosforilacijo EGFR.
Caution should be exercised when ciprofloxacin or potent CYP1A2 inhibitors (e.g. fluvoxamine) are combined with erlotinib. 
Pri kombinaciji ciprofloksacina ali močnega zaviralca CYP1A2 (npr. fluvoksamina) z erlotinibom je potrebna previdnost.
Adequate contraceptive methods should be used during therapy, and for at least 2 weeks after completing therapy. 
Med zdravljenjem z zdravilom Tarceva in najmanj 2 tedna po zaključku zdravljenja je treba uporabljati zanesljive kontracepcijske metode.
The potent effectiveness of erlotinib in blocking EGFR-mediated signalling in these EGFR mutation positive tumours is attributed to the tight binding of erlotinib to the ATP-binding site in the mutated kinase domain of the EGFR. 
Trdni vezavi erlotiniba na vezavno mesto za ATP v mutirani kinazni domeni EGFR lahko pripišemo veliko učinkovitost erlotiniba pri blokadi z EGFR posredovanega signaliziranja v tumorjih z EGFRaktivirajočimi mutacijami.
Confounding factors have included pre-existing liver disease or concomitant hepatotoxic medications. 
K njenemu nastanku je lahko pripomogla predhodno obstoječa jetrna bolezen ali sočasno jemanje hepatotoksičnih zdravil.
Potential interactions may occur with active substances which are metabolised by, or are inhibitors or inducers of, these enzymes. 
Z učinkovinami, ki se presnavljajo s temi encimi, jih zavirajo ali pa so njihovi induktorji, lahko pride do interakcij.
A mild phototoxic skin reaction was observed in rats after UV irradiation. 
Pri podganah so po obsevanju z UV-žarki opazili blago fototoksično kožno reakcijo.
INFORMATION IN BRAILLE tarceva 100 mg 
PODATKI V BRAILLOVI PISAVI tarceva 100 mg
Metabolism and nutrition disorders Anorexia Weight decreased very common very common 
Presnovne in prehranske motnje anoreksija zmanjšanje telesne mase zelo pogosti zelo pogosti
Co-administration of gemcitabine had no effect on erlotinib plasma clearance. 
Sočasno dajanje gemcitabina ni imelo vpliva na plazemski očistek erlotiniba.
In the pancreatic cancer study in combination with gemcitabine, the incidence of ILD-like events was 2.5% in the Tarceva plus gemcitabine group versus 0.4% in the placebo plus gemcitabine treated group. 
V študiji pri bolnikih z rakom trebušne slinavke, v kombinaciji z gemcitabinom, je bila incidenca dogodkov, podobnih intersticijski bolezni pljuč, 2,5 % v skupini, ki je prejemala zdravilo Tarceva in gemcitabin, v primerjavi z 0,4 % v skupini, ki je prejemala placebo in gemcitabin.
In a clinical study, the concomitant use of erlotinib with ketoconazole (200 mg orally twice daily for 5 days), a potent CYP3A4 inhibitor, resulted in an increase of erlotinib exposure (86% of AUC and 69% of Cmax). 
V klinični študiji je sočasna uporaba erlotiniba in močnega zaviralca CYP3A4, ketokonazola (200 mg peroralno dvakrat na dan 5 dni), povzročila povečano izpostavljenost erlotinibu (86 % AUC in 69 % Cmax).
Rash*** 
Celokupno preživetje ***
-Pancreatic cancer (Tarceva administered concurrently with gemcitabine in study PA.3) 
- Rak trebušne slinavke (zdravilo Tarceva v kombinaciji z gemcitabinom v študiji PA.3)
INFORMATION IN BRAILLE tarceva 150 mg 
PODATKI V BRAILLOVI PISAVI tarceva 150 mg
Tarceva is given in combination with gemcitabine treatment. 
Zdravilo Tarceva boste dobili v kombinaciji z gemcitabinom.
However, when Tarceva was dosed in a staggered manner 2 hours before or 10 hours after ranitidine 150 mg b.i.d., erlotinib exposure [AUC] and maximum concentrations [Cmax] decreased only by 15% and 17%, respectively. 
Ko pa so zdravilo Tarceva dajali ločeno, to je 2 uri pred ali 10 ur po 150 mg ranitidina (ki so ga bolniki jemali dvakrat na dan), se je izpostavljenost erlotinibu [AUC] zmanjšala samo za 15 %, maksimalna koncentracija [Cmax] pa samo za 17 %.
Safety data were comparable between the 300 mg and 150 mg doses; however, there was a numerical increase in the incidence of rash, interstitial lung disease and diarrhoea, in patients receiving the higher dose of erlotinib. 
Podatki o varnosti so bili med odmerkoma 300 mg in 150 mg primerljivi; vendar pa je bilo pri bolnikih, ki so prejemali večji odmerek erlotiniba, številčno več pojavnosti izpuščaja, intersticijske bolezni pljuč in driske.
However, smokers had an increased rate of erlotinib clearance. 
Pri kadilcih je bila hitrost izločanja erlotiniba večja.
The geometric mean of the C24h was 288 ng/mL in the non-smokers and 34.8 ng/mL in the smokers with a mean ratio of 12.1% (95% CI: 4.82 to 30.2, p = 0.0001). 
Geometrijska sredina C24h je bila 288 ng/ml pri nekadilcih in 34,8 ng/ml pri kadilcih s povprečnim razmerjem 12,1 % (95-% interval zaupanja: 4,82-30,2; p = 0,0001).
The efficacy and safety of Tarceva as maintenance after first-line chemotherapy for NSCLC was investigated in a randomised, double-blind, placebo-controlled trial (BO18192, SATURN). 
Učinkovitost in varnost zdravila Tarceva v vzdrževalnem zdravljenju po kemoterapiji v prvi liniji pri nedrobnoceličnem raku pljuč so proučevali v randomiziranem, dvojno slepem, s placebom primerjanem preskušanju (BO18192, SATURN).
When erlotinib was co-administered with ciprofloxacin, a moderate CYP1A2 inhibitor, the erlotinib exposure [AUC] increased significantly by 39%, while no statistically significant change in Cmax was found. 
Ko so erlotinib dajali skupaj s ciprofloksacinom, srednje močnim zaviralcem CYP1A2, se je izpostavljenost erlotinibu [AUC] značilno povečala za 39 %, sprememba maksimalne koncentracije (Cmax) pa ni bila statistično značilna.
After oral administration, erlotinib peak plasma levels are obtained in approximately 4 hours after oral dosing. 
Po peroralnem zaužitju so maksimalne koncentracije erlotiniba v plazmi dosežene v približno 4 urah.
Therefore, caution should be used when erlotinib is combined with a potent CYP3A4 inhibitor, e.g. azole antifungals (i.e. ketoconazole, itraconazole, voriconazole), protease inhibitors, erythromycin or clarithromycin. 
Pri sočasnem jemanju erlotiniba in močnih zaviralcev CYP3A4, kot so azolni antimikotiki (npr. ketokonazol, itrakonazol, vorikonazol), zaviralci proteaz, eritromicin ali klaritromicin, je zato potrebna previdnost.
Erlotinib binds to serum albumin and alpha-1 acid glycoprotein (AAG). 
Erlotinib se veže na serumski albumin in alfa-1 kisli glikoprotein.
Erlotinib is a substrate for the P-glycoprotein active substance transporter. 
Erlotinib je substrat P-glikoproteina, prenašalca učinkovin.
See sections 4.2, 4.4, 4.5, and 
Glejte poglavja 4.2, 4.4, 4.5 in 5.2.
4 In clinical studies, some cases have been associated with concomitant warfarin administration and some with concomitant NSAID administration (see section 4.5). 
V kliničnih študijah so bile v nekaterih primerih povezane s sočasnim jemanjem varfarina, v nekaterih primerih pa s sočasnim jemanjem nesteroidnih protivnetnih zdravil (glejte poglavje 4.5).
Erlotinib is metabolised in the liver by the hepatic cytochromes in humans, primarily CYP3A4 and to a lesser extent by CYP1A2. 
Erlotinib se pri ljudeh presnavlja v jetrih z jetrnimi citokromi, primarno s CYP3A4 in v manjši meri s CYP1A2.
LIST OF EXCIPIENTS Contains lactose monohydrate. 
SEZNAM POMOŽNIH SNOVI Zdravilo vsebuje tudi laktozo monohidrat.
The primary endpoint was survival. 
Primarni cilj preskušanja je bilo preživetje.
Respiratory, thoracic and mediastinal disorders Dyspnoea Cough very common very common 
Bolezni dihal, prsnega koša in mediastinalnega prostora dispneja kašelj zelo pogosti zelo pogosti
Patient factors, which correlated with erlotinib pharmacokinetics, were serum total bilirubin, AAG and current smoking. 
Dejavniki, ki so bili pri bolniku povezani s farmakokinetiko erlotiniba, so bili serumski celokupni bilirubin, koncentracije alfa-1 kislega glikoproteina in trenutno kajenje.
Do not breast-feed if you are being treated with Tarceva, and for at least 2 weeks after taking the last tablet. 
Med zdravljenjem z zdravilom Tarceva in še najmanj 2 meseca po zadnji tableti zdravila ne dojite.
The objective response rate by RECIST in the Tarceva group was 8.9% (95% CI, 6.4 to 12.0). 
Objektivni odgovor na zdravljenje po kriterijih RECIST (Response Evaluation Criteria In Solid Tumours) je v skupini, ki je jemala zdravilo Tarceva, znašal 8,9 % (95-% interval zaupanja; 6,4-12,0).
The BO25460 (IUNO) study was conducted in 643 patients with advanced NSCLC whose tumors did not harbor an EGFR-activating mutation (exon 19 deletion or exon 21 L858R mutation) and who had not experienced disease progression after four cycles of platinum-based chemotherapy. 
Študijo BO25460 (IUNO) so izvedli pri 643 bolnikih z napredovalim nedrobnoceličnim rakom pljuč, katerih tumorji niso imeli EGFR-aktivirajočih mutacij (delecije eksona 19 ali mutacije eksona 21
The geometric mean of the AUC0-inf was 18726 ng•h/mL in the non-smokers and 6718 ng•h/mL in the smokers with a mean ratio of 35.9% (95% CI: 23.7 to 54.3, p < 0.0001). 
Geometrijska sredina AUC0-∞ je bila 18.726 ng•h/ml pri nekadilcih in 6.718 ng•h/ml pri kadilcih s povprečnim razmerjem 35,9 % (95-% interval zaupanja: 23,7-54,3; p < 0,0001).
In a randomised double-blind study (BR.21; Tarceva administered as second line therapy), rash (75%) and diarrhoea (54%) were the most commonly reported adverse drug reactions (ADRs). 
V randomizirani, dvojno slepi študiji (BR.21; zdravilo Tarceva v drugi liniji zdravljenja) sta bila najpogostejša neželena učinka, o katerih so poročali, kožni izpuščaj (75 %) in driska (54 %).
Rash and diarrhoea resulted in discontinuation of Tarceva in 1% and <1% of patients, respectively, in study BO18192, while no patients discontinued for rash or diarrhoea in BO25460. 
Zdravljenje z zdravilom Tarceva so v študiji BO18192 zaradi kožnega izpuščaja ukinili pri 1 % bolnikov in zaradi driske pri < 1 % bolnikov, v študiji BO25460 pa zaradi kožnega izpuščaja ali driske niso ukinili zdravljenja pri nobenem bolniku.